Drawing upon strong multi-jurisdictional capabilities- predominantly with Europe- the WilmerHale team is ‘calm under pressure’ when handling IPOs, follow-on public offerings, and complex SPAC transactions. Representing both issuers and managers, the practice shows a special focus on the medtech and medical industries, with the New York-based duo of Brian Johnson and Lisa Firenze leading the outfit. In Boston, Stuart Falber regularly counsels mature public companies and investment banks, and Molly Fox is a corporate finance expert, while Craig Hilts is knowledgeable on convertible debt offerings. Also in Boston, Cynthia Mazareas and Caroline Dotolo are also noted as key.
Legal 500 redaktioneller Kommentar

Referenzen

Unabhängig vom Legal 500-Forschungsteam zusammengestellt.

  • 'Scott Lunin is a thorough subject matter expert. Feel completely confident in his counsel. And he takes the time to explain complex matters. Had helped get through unique matters with NASDAQ.'

Kernmandanten

  • Medtronic, Inc.
  • State Street Corporation
  • MKS Instruments, Inc.
  • Analog Devices, Inc.
  • Thermo Fisher Scientific
  • Agios Pharmaceuticals
  • MicroStrategy Incorporated
  • Casella Waste Systems, Inc.
  • McCormick & Company, Incorporated
  • Choice Hotels International, Inc.

Highlight-Mandate

  • Advised Medtronic in its public offering of €850 million aggregate principal amount of 3.650% Senior Notes due 2029, €850 million aggregate principal amount of 3.875% Senior Notes due 2036, €600 million aggregate principal amount of 4.150% Senior Notes due 2043 and €700 million aggregate principal amount of 4.150% Senior Notes due 2053.
  • Advised Thermo Fisher Scientific as US special counsel in connection with its inaugural offer and sale of CHF-denominated bonds, in an offering that was the largest issuance by a foreign issuer of Swiss franc bonds in seven years, worth CHF $1.07 billion.
  • Advised Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), in its agreement to sell its rights to its 15% royalty on potential $1 billion US net sales of Servier’s vorasidenib to Royalty Pharma.

Anwält*innen

Praxisleitung

Brian Johnson; Lisa Firenze

Weitere Kernanwält*innen

Stuart Falber; Molly Fox; Craig Hilts; Cynthia Mazareas; Caroline Dotolo; Scott Lunin